ES2158943T3 - Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos. - Google Patents

Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos.

Info

Publication number
ES2158943T3
ES2158943T3 ES95914792T ES95914792T ES2158943T3 ES 2158943 T3 ES2158943 T3 ES 2158943T3 ES 95914792 T ES95914792 T ES 95914792T ES 95914792 T ES95914792 T ES 95914792T ES 2158943 T3 ES2158943 T3 ES 2158943T3
Authority
ES
Spain
Prior art keywords
precursor
peptides derived
same
tumor rejection
rejection antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914792T
Other languages
English (en)
Inventor
Cornelis J M Melief
M W Visseren
W M Kast
Der Bruggen Pierre Van
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Cancer Research
Leiden University
Original Assignee
Ludwig Cancer Research
Leiden University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Cancer Research, Leiden University filed Critical Ludwig Cancer Research
Application granted granted Critical
Publication of ES2158943T3 publication Critical patent/ES2158943T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION DESCRIBE PEPTIDOS DERIVADOS DEL PRECURSOR MAGE NEN A LAS MOLECULAS HLA AN LA PRODUCCION DE CELULAS T CITOLITICAS. LOS "CTLS" RESULTANTES SON ESPECIFICOS PARA COMPLEJOS DE HLA OS COMPLEJOS PUEDEN UTILIZARSE PARA GENERAR ANTICUERPOS MONOCLONALES. LAS CELULAS T CITOLITICAS PRODUCIDAS PUEDEN UTILIZARSE EN EL CONTEXTO DE LA INMUNOTERAPIA, COMO EN UNA TRANSFERENCIA ADOPTIVA.
ES95914792T 1994-03-24 1995-03-21 Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos. Expired - Lifetime ES2158943T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/217,188 US5554724A (en) 1994-03-24 1994-03-24 Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

Publications (1)

Publication Number Publication Date
ES2158943T3 true ES2158943T3 (es) 2001-09-16

Family

ID=22810016

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914792T Expired - Lifetime ES2158943T3 (es) 1994-03-24 1995-03-21 Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos.

Country Status (17)

Country Link
US (3) US5554724A (es)
EP (1) EP0810870B1 (es)
JP (1) JP3360137B2 (es)
CN (1) CN1149257A (es)
AT (1) ATE201214T1 (es)
AU (1) AU682597B2 (es)
CA (1) CA2186006A1 (es)
DE (1) DE69520959T2 (es)
DK (1) DK0810870T3 (es)
ES (1) ES2158943T3 (es)
FI (1) FI963780L (es)
GR (1) GR3036320T3 (es)
NO (1) NO963918L (es)
NZ (2) NZ283561A (es)
PT (1) PT810870E (es)
WO (1) WO1995025530A1 (es)
ZA (1) ZA952375B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
EP0954601A4 (en) * 1996-03-20 2004-08-18 Genzyme Corp METHOD FOR DETECTING CYTOTOXIC T-CELL EPITOPES
US6087441A (en) 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
EP1012173B1 (en) 1997-06-23 2007-10-31 Ludwig Institute For Cancer Research Isolated decapeptides which bind to hla molecules, and the use thereof
US6025470A (en) * 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
CN1262562C (zh) * 1998-07-28 2006-07-05 株式会社绿多肽 来源于sart－1的hla－a2限制性肿瘤抗原肽
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
SI1620456T1 (sl) * 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
BR112013023027A2 (pt) 2011-03-07 2016-08-16 Creative Neail Design Inc composições e métodos para esmaltes de unha curáveis por uv
EP2825572B1 (en) 2012-03-15 2022-07-27 ExxonMobil Chemical Patents Inc. Oxygen tailoring of polyethylene
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
SG49008A1 (en) * 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
US6147187A (en) 2000-11-14
US5554724A (en) 1996-09-10
JPH10502329A (ja) 1998-03-03
NZ329695A (en) 2000-05-26
ATE201214T1 (de) 2001-06-15
DK0810870T3 (da) 2001-07-23
NZ283561A (en) 1998-04-27
PT810870E (pt) 2001-09-28
FI963780A7 (fi) 1996-09-23
AU2189395A (en) 1995-10-09
WO1995025530A1 (en) 1995-09-28
JP3360137B2 (ja) 2002-12-24
ZA952375B (en) 1995-12-15
FI963780A0 (fi) 1996-09-23
AU682597B2 (en) 1997-10-09
US6063900A (en) 2000-05-16
CA2186006A1 (en) 1995-09-28
NO963918L (no) 1996-11-20
FI963780L (fi) 1996-09-23
EP0810870A1 (en) 1997-12-10
NO963918D0 (no) 1996-09-19
EP0810870B1 (en) 2001-05-16
EP0810870A4 (en) 1998-11-25
DE69520959T2 (de) 2002-03-28
GR3036320T3 (en) 2001-11-30
CN1149257A (zh) 1997-05-07
DE69520959D1 (de) 2001-06-21

Similar Documents

Publication Publication Date Title
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
Castelli et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
ES2174931T3 (es) Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1.
CO4810234A1 (es) Vacunas para el tratamiento de virus papiloma humano
ES2154728T3 (es) Peptidos aislados derivados de precursores del antigeno de rechazo de tumores mage que forman un complejo con moleculas del hla-a2.
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
ES2104565T3 (es) Determinantes anti-receptor de celulas t como tratamiento de enfermedades autoinmunes.
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
ES2080717T3 (es) Hibridomas productores de anticuerpos monoclonales para nuevos epitopos de mucina.
JP2020534313A5 (es)
AR038700A1 (es) Anticuerpos monoclonales anti-tenascina humana
Jäger et al. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals
FI963781A0 (fi) Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-molekyylejä, ja niiden käyttöjä
ES2123558T3 (es) Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc.
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
ES2126145T3 (es) Redireccionamiento de anticuerpos.
Kobayashi et al. Defining MHC class II T helper epitopes for WT1 tumor antigen
Brimnes et al. Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion
ITRM920350A1 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
EA200702202A1 (ru) Идентификация представленных hla-a2 т-клеточных эпитопов, полученных из раково-эмбрионального антиген-незрелого рецепторного белка ламинила, и их применение
Voskens et al. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome
PT996636E (pt) Antigenio ha-1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 810870

Country of ref document: ES